GEOVAX LABS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
GEOVAX LABS, INC. (GOVX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $965.11 thousand as of 2025-12-31, per its S-1 filed 2026-09-17.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-09-17
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $965.11K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $676.25K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $552.89K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $330.55K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $965.11K S-1 · filed 2026-09-17 |
| 2024-12-31 | $676.25K S-1 · filed 2026-09-17 |
| 2023-12-31 | $552.89K 10-K · filed 2025-03-27 |
| 2022-12-31 | $330.55K 10-K · filed 2024-02-29 |
| 2021-12-31 | $129.47K 10-K · filed 2023-03-23 |
| 2020-12-31 | $4.87K 10-K · filed 2022-03-09 |
| 2019-12-31 | $1.88M 10-K · filed 2021-03-23 |
| 2018-12-31 | $1.81M 10-K · filed 2020-03-24 |
| 2017-12-31 | $1.71M 10-K · filed 2019-03-26 |
| 2016-12-31 | $2.75M 10-K · filed 2018-03-23 |
| 2015-12-31 | $2.42M 10-K · filed 2017-03-24 |
| 2014-12-31 | $2.40M 10-K · filed 2016-03-16 |
| 2013-12-31 | $2.23M 10-K · filed 2015-03-20 |
| 2012-12-31 | $2.10M 10-K · filed 2014-03-14 |
| 2011-12-31 | $1.99M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B |